{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:49:00Z","timestamp":1793994540905,"version":"4.8.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","award":["KAW 2015.0278"],"award-info":[{"award-number":["KAW 2015.0278"]}],"id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012529","name":"Insamlingsstiftelsen Diabetes Wellness Network Sverige","doi-asserted-by":"publisher","award":["757_2015PG"],"award-info":[{"award-number":["757_2015PG"]}],"id":[{"id":"10.13039\/501100012529","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University Of Umea"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Type 2 diabetes (T2D), alike Parkinson\u2019s disease (PD), belongs to the group of protein misfolding diseases (PMDs), which share aggregation of misfolded proteins as a hallmark. Although the major aggregating peptide in \u03b2-cells of T2D patients is Islet Amyloid Polypeptide (IAPP), alpha-synuclein (\u03b1Syn), the aggregating peptide in substantia nigra neurons of PD patients, is expressed also in \u03b2-cells. Here we show that \u03b1Syn, encoded by <jats:italic>Snca<\/jats:italic>, is a component of amyloid extracted from pancreas of transgenic mice overexpressing human <jats:italic>IAPP<\/jats:italic> (denoted <jats:italic>hIAPPtg<\/jats:italic> mice) and from islets of T2D individuals. Notably, \u03b1Syn dose-dependently promoted IAPP fibril formation in vitro and tail-vein injection of \u03b1Syn in <jats:italic>hIAPPtg<\/jats:italic> mice enhanced \u03b2-cell amyloid formation in vivo whereas \u03b2-cell amyloid formation was reduced in <jats:italic>hIAPPtg<\/jats:italic> mice on a <jats:italic>Snca <\/jats:italic><jats:sup><jats:italic>\u2212\/\u2212<\/jats:italic><\/jats:sup> background. Taken together, our findings provide evidence that \u03b1Syn and IAPP co-aggregate both in vitro and in vivo, suggesting a role for \u03b1Syn in \u03b2-cell amyloid formation.<\/jats:p>","DOI":"10.1038\/s41598-020-77409-z","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T11:16:29Z","timestamp":1606216589000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["\u03b1-Synuclein promotes IAPP fibril formation in vitro and \u03b2-cell amyloid formation in vivo in mice"],"prefix":"10.1038","volume":"10","author":[{"given":"Marija","family":"Mucibabic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4r","family":"Steneberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmelie","family":"Lidh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurate","family":"Straseviciene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Ziolkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Lindahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Edlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,24]]},"reference":[{"key":"77409_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.molmed.2015.04.005","volume":"21","author":"A Mukherjee","year":"2015","unstructured":"Mukherjee, A., Morales-Scheihing, D., Butler, P. C. & Soto, C. Type 2 diabetes as a protein misfolding disease. Trends Mol. Med. 21, 439\u2013449 (2015).","journal-title":"Trends Mol. Med."},{"key":"77409_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1146\/annurev-biochem-061516-045115","volume":"86","author":"F Chiti","year":"2017","unstructured":"Chiti, F. & Dobson, C. M. Protein misfolding, amyloid formation, and human disease: A summary of progress over the last decade. Annu. Rev. Biochem. 86, 27\u201368 (2017).","journal-title":"Annu. Rev. Biochem."},{"key":"77409_CR3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/BF01219652","volume":"15","author":"P Westermark","year":"1978","unstructured":"Westermark, P. & Wilander, E. The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Diabetologia 15, 417\u2013421 (1978).","journal-title":"Diabetologia"},{"issue":"Suppl","key":"77409_CR4","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1016\/0168-8227(95)01075-O","volume":"28","author":"A Clark","year":"1995","unstructured":"Clark, A. et al. Pancreatic pathology in non-insulin dependent diabetes (NIDDM). Diabetes Res. Clin. Pract. 28(Suppl), S39-47 (1995).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"77409_CR5","first-page":"151","volume":"9","author":"A Clark","year":"1988","unstructured":"Clark, A. et al. Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: Quantitative changes in the pancreas in type 2 diabetes. Diabetes Res. 9, 151\u2013159 (1988).","journal-title":"Diabetes Res."},{"key":"77409_CR6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1210\/er.2007-0037","volume":"29","author":"L Haataja","year":"2008","unstructured":"Haataja, L., Gurlo, T., Huang, C. J. & Butler, P. C. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr. Rev. 29, 303\u2013316 (2008).","journal-title":"Endocr. Rev."},{"key":"77409_CR7","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1210\/jc.2004-0405","volume":"89","author":"RL Hull","year":"2004","unstructured":"Hull, R. L., Westermark, G. T., Westermark, P. & Kahn, S. E. Islet amyloid: A critical entity in the pathogenesis of type 2 diabetes. J. Clin. Endocrinol. Metab. 89, 3629\u20133643 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"77409_CR8","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1152\/physrev.00042.2009","volume":"91","author":"P Westermark","year":"2011","unstructured":"Westermark, P., Andersson, A. & Westermark, G. T. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol. Rev. 91, 795\u2013826 (2011).","journal-title":"Physiol. Rev."},{"key":"77409_CR9","doi-asserted-by":"publisher","first-page":"E276","DOI":"10.1152\/ajpendo.00262.2010","volume":"300","author":"X Geng","year":"2011","unstructured":"Geng, X. et al. Alpha-synuclein binds the K(ATP) channel at insulin-secretory granules and inhibits insulin secretion. Am. J. Physiol. Endocrinol. Metab. 300, E276-286 (2011).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"77409_CR10","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.2337\/db12-1045","volume":"62","author":"P Steneberg","year":"2013","unstructured":"Steneberg, P. et al. The type 2 diabetes-associated gene ide is required for insulin secretion and suppression of alpha-synuclein levels in beta-cells. Diabetes 62, 2004\u20132014 (2013).","journal-title":"Diabetes"},{"key":"77409_CR11","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00401-018-1832-0","volume":"135","author":"I Martinez-Valbuena","year":"2018","unstructured":"Martinez-Valbuena, I. et al. Interaction of amyloidogenic proteins in pancreatic beta cells from subjects with synucleinopathies. Acta Neuropathol. 135, 877\u2013886 (2018).","journal-title":"Acta Neuropathol."},{"key":"77409_CR12","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1001\/archneur.61.5.661","volume":"61","author":"Z Arvanitakis","year":"2004","unstructured":"Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A. & Bennett, D. A. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch. Neurol. 61, 661\u2013666 (2004).","journal-title":"Arch. Neurol."},{"key":"77409_CR13","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nrneurol.2010.130","volume":"6","author":"C Sims-Robinson","year":"2010","unstructured":"Sims-Robinson, C., Kim, B., Rosko, A. & Feldman, E. L. How does diabetes accelerate Alzheimer disease pathology?. Nat. Rev. Neurol. 6, 551\u2013559 (2010).","journal-title":"Nat. Rev. Neurol."},{"key":"77409_CR14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.pneurobio.2016.10.001","volume":"145\u2013146","author":"D Athauda","year":"2016","unstructured":"Athauda, D. & Foltynie, T. Insulin resistance and Parkinson\u2019s disease: A new target for disease modification?. Prog. Neurobiol. 145\u2013146, 98\u2013120 (2016).","journal-title":"Prog. Neurobiol."},{"key":"77409_CR15","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1212\/WNL.0000000000005771","volume":"91","author":"E De Pablo-Fernandez","year":"2018","unstructured":"De Pablo-Fernandez, E., Goldacre, R., Pakpoor, J., Noyce, A. J. & Warner, T. T. Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study. Neurology 91, e139\u2013e142 (2018).","journal-title":"Neurology"},{"key":"77409_CR16","doi-asserted-by":"publisher","first-page":"842","DOI":"10.2337\/dc06-2011","volume":"30","author":"G Hu","year":"2007","unstructured":"Hu, G., Jousilahti, P., Bidel, S., Antikainen, R. & Tuomilehto, J. Type 2 diabetes and the risk of Parkinson\u2019s disease. Diabetes Care 30, 842\u2013847 (2007).","journal-title":"Diabetes Care"},{"key":"77409_CR17","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.parkreldis.2012.03.010","volume":"18","author":"ML Wahlqvist","year":"2012","unstructured":"Wahlqvist, M. L. et al. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson\u2019s disease occurring with type 2 diabetes in a Taiwanese population cohort. Parkinsonism Relat. Disord. 18, 753\u2013758 (2012).","journal-title":"Parkinsonism Relat. Disord."},{"key":"77409_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3233\/JPD-181305","volume":"8","author":"E Hogg","year":"2018","unstructured":"Hogg, E. et al. High prevalence of undiagnosed insulin resistance in non-diabetic subjects with Parkinson\u2019s disease. J. Parkinsons Dis. 8, 259\u2013265 (2018).","journal-title":"J. Parkinsons Dis."},{"key":"77409_CR19","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nrneurol.2017.185","volume":"14","author":"SE Arnold","year":"2018","unstructured":"Arnold, S. E. et al. Brain insulin resistance in type 2 diabetes and Alzheimer disease: Concepts and conundrums. Nat. Rev. Neurol. 14, 168\u2013181 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"77409_CR20","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.expneurol.2017.08.001","volume":"298","author":"DJ Surmeier","year":"2017","unstructured":"Surmeier, D. J., Halliday, G. M. & Simuni, T. Calcium, mitochondrial dysfunction and slowing the progression of Parkinson\u2019s disease. Exp. Neurol. 298, 202\u2013209 (2017).","journal-title":"Exp. Neurol."},{"key":"77409_CR21","doi-asserted-by":"publisher","first-page":"795","DOI":"10.3390\/biom4030795","volume":"4","author":"A Rcom-H'cheo-Gauthier","year":"2014","unstructured":"Rcom-H\u2019cheo-Gauthier, A., Goodwin, J. & Pountney, D. L. Interactions between calcium and alpha-synuclein in neurodegeneration. Biomolecules 4, 795\u2013811 (2014).","journal-title":"Biomolecules"},{"key":"77409_CR22","doi-asserted-by":"publisher","first-page":"e1003537","DOI":"10.1371\/journal.ppat.1003537","volume":"9","author":"R Morales","year":"2013","unstructured":"Morales, R., Moreno-Gonzalez, I. & Soto, C. Cross-seeding of misfolded proteins: Implications for etiology and pathogenesis of protein misfolding diseases. PLoS Pathog. 9, e1003537 (2013).","journal-title":"PLoS Pathog."},{"key":"77409_CR23","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.ajpath.2014.11.016","volume":"185","author":"ME Oskarsson","year":"2015","unstructured":"Oskarsson, M. E. et al. In vivo seeding and cross-seeding of localized amyloidosis: A molecular link between type 2 diabetes and Alzheimer disease. Am. J. Pathol. 185, 834\u2013846 (2015).","journal-title":"Am. J. Pathol."},{"key":"77409_CR24","doi-asserted-by":"publisher","first-page":"11282","DOI":"10.1073\/pnas.90.23.11282","volume":"90","author":"K Ueda","year":"1993","unstructured":"Ueda, K. et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. U S A 90, 11282\u201311286 (1993).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"77409_CR25","doi-asserted-by":"publisher","first-page":"5036","DOI":"10.1073\/pnas.87.13.5036","volume":"87","author":"P Westermark","year":"1990","unstructured":"Westermark, P., Engstrom, U., Johnson, K. H., Westermark, G. T. & Betsholtz, C. Islet amyloid polypeptide: Pinpointing amino acid residues linked to amyloid fibril formation. Proc. Natl. Acad. Sci. U S A 87, 5036\u20135040 (1990).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"77409_CR26","doi-asserted-by":"publisher","first-page":"12473","DOI":"10.1073\/pnas.1610371113","volume":"113","author":"I Horvath","year":"2016","unstructured":"Horvath, I. & Wittung-Stafshede, P. Cross-talk between amyloidogenic proteins in type-2 diabetes and Parkinson\u2019s disease. Proc. Natl. Acad. Sci. U S A 113, 12473\u201312477 (2016).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"77409_CR27","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1021\/acschemneuro.5b00192","volume":"6","author":"R Hu","year":"2015","unstructured":"Hu, R., Zhang, M., Chen, H., Jiang, B. & Zheng, J. Cross-seeding interaction between beta-amyloid and human islet amyloid polypeptide. ACS Chem. Neurosci. 6, 1759\u20131768 (2015).","journal-title":"ACS Chem. Neurosci."},{"key":"77409_CR28","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.bbapap.2019.05.003","volume":"1867","author":"K Afitska","year":"2019","unstructured":"Afitska, K., Fucikova, A., Shvadchak, V. V. & Yushchenko, D. A. alpha-Synuclein aggregation at low concentrations. Biochim. Biophys. Acta Proteins Proteom. 1867, 701\u2013709 (2019).","journal-title":"Biochim. Biophys. Acta Proteins Proteom."},{"key":"77409_CR29","doi-asserted-by":"publisher","first-page":"14587","DOI":"10.1074\/jbc.M117.774893","volume":"292","author":"M Bakou","year":"2017","unstructured":"Bakou, M. et al. Key aromatic\/hydrophobic amino acids controlling a cross-amyloid peptide interaction versus amyloid self-assembly. J. Biol. Chem. 292, 14587\u201314602 (2017).","journal-title":"J. Biol. Chem."},{"key":"77409_CR30","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/j.1471-4159.2012.07847.x","volume":"122","author":"K Ono","year":"2012","unstructured":"Ono, K., Takahashi, R., Ikeda, T. & Yamada, M. Cross-seeding effects of amyloid beta-protein and alpha-synuclein. J. Neurochem. 122, 883\u2013890 (2012).","journal-title":"J. Neurochem."},{"key":"77409_CR31","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1038\/srep04267","volume":"4","author":"Y Bram","year":"2014","unstructured":"Bram, Y. et al. Apoptosis induced by islet amyloid polypeptide soluble oligomers is neutralized by diabetes-associated specific antibodies. Sci. Rep. 4, 4267 (2014).","journal-title":"Sci. Rep."},{"key":"77409_CR32","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.semcdb.2011.04.002","volume":"22","author":"I Moreno-Gonzalez","year":"2011","unstructured":"Moreno-Gonzalez, I. & Soto, C. Misfolded protein aggregates: Mechanisms, structures and potential for disease transmission. Semin. Cell Dev. Biol. 22, 482\u2013487 (2011).","journal-title":"Semin. Cell Dev. Biol."},{"key":"77409_CR33","doi-asserted-by":"publisher","first-page":"560","DOI":"10.3389\/fnins.2019.00560","volume":"13","author":"E Colla","year":"2019","unstructured":"Colla, E. Linking the endoplasmic reticulum to Parkinson\u2019s disease and alpha-synucleinopathy. Front. Neurosci. 13, 560 (2019).","journal-title":"Front. Neurosci."},{"key":"77409_CR34","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.1172\/JCI127330","volume":"130","author":"RE Musgrove","year":"2019","unstructured":"Musgrove, R. E. et al. Oxidative stress in vagal neurons promotes parkinsonian pathology and intercellular alpha-synuclein transfer. J. Clin. Invest. 130, 3738\u20133753 (2019).","journal-title":"J. Clin. Invest."},{"key":"77409_CR35","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00125-009-1347-2","volume":"52","author":"M Masini","year":"2009","unstructured":"Masini, M. et al. Autophagy in human type 2 diabetes pancreatic beta cells. Diabetologia 52, 1083\u20131086 (2009).","journal-title":"Diabetologia"},{"key":"77409_CR36","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2337\/db12-1326","volume":"62","author":"S Costes","year":"2013","unstructured":"Costes, S., Langen, R., Gurlo, T., Matveyenko, A. V. & Butler, P. C. beta-Cell failure in type 2 diabetes: A case of asking too much of too few?. Diabetes 62, 327\u2013335 (2013).","journal-title":"Diabetes"},{"key":"77409_CR37","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/biom4010020","volume":"4","author":"A Relini","year":"2013","unstructured":"Relini, A., Marano, N. & Gliozzi, A. Misfolding of amyloidogenic proteins and their interactions with membranes. Biomolecules 4, 20\u201355 (2013).","journal-title":"Biomolecules"},{"key":"77409_CR38","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1111\/febs.14587","volume":"285","author":"ML Choi","year":"2018","unstructured":"Choi, M. L. & Gandhi, S. Crucial role of protein oligomerization in the pathogenesis of Alzheimer\u2019s and Parkinson\u2019s diseases. FEBS J. 285, 3631\u20133644 (2018).","journal-title":"FEBS J."},{"key":"77409_CR39","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1093\/hmg\/ddq038","volume":"19","author":"YM Kuo","year":"2010","unstructured":"Kuo, Y. M. et al. Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum. Mol. Genet. 19, 1633\u20131650 (2010).","journal-title":"Hum. Mol. Genet."},{"key":"77409_CR40","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/mds.27556","volume":"34","author":"DP Breen","year":"2019","unstructured":"Breen, D. P., Halliday, G. M. & Lang, A. E. Gut-brain axis and the spread of alpha-synuclein pathology: Vagal highway or dead end?. Mov. Disord. 34, 307\u2013316 (2019).","journal-title":"Mov. Disord."},{"key":"77409_CR41","doi-asserted-by":"crossref","unstructured":"Kim, S., et al. Transneuronal propagation of pathologic alpha-synuclein from the gut to the brain models Parkinson's disease. Neuron 103, 627\u2013641 e627 (2019).","DOI":"10.1016\/j.neuron.2019.05.035"},{"key":"77409_CR42","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1096\/fj.03-0098fje","volume":"17","author":"OM El-Agnaf","year":"2003","unstructured":"El-Agnaf, O. M. et al. Alpha-synuclein implicated in Parkinson\u2019s disease is present in extracellular biological fluids, including human plasma. FASEB J 17, 1945\u20131947 (2003).","journal-title":"FASEB J"},{"key":"77409_CR43","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0168-8227(92)90074-2","volume":"15","author":"S Enoki","year":"1992","unstructured":"Enoki, S. et al. Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Diabetes Res. Clin. Pract. 15, 97\u2013102 (1992).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"77409_CR44","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0026-0495(97)90175-X","volume":"46","author":"B Ahren","year":"1997","unstructured":"Ahren, B. et al. Dissociated insulinotropic sensitivity to glucose and carbachol in high-fat diet-induced insulin resistance in C57BL\/6J mice. Metabolism 46, 97\u2013106 (1997).","journal-title":"Metabolism"},{"key":"77409_CR45","doi-asserted-by":"crossref","unstructured":"Ly, P.T., Cai, F. & Song, W. Detection of neuritic plaques in Alzheimer's disease mouse model. J. Vis. Exp. (2011).","DOI":"10.3791\/2831"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77409-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77409-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77409-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T23:36:40Z","timestamp":1670369800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77409-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,24]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["77409"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-77409-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,24]]},"assertion":[{"value":"4 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.E. is a cofounder, shareholder, and consultant of the unlisted biotech company Betagenon AB. M.M., P.S., E.Lidh, J.S., A.Z., U.D. and E.Lindahl have no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20438"}}